Exporting cannabis to Israel as a Canadian Licensed Producer requires a valid Health Canada export permit, acceptance of your quality certification by the Israeli Medical Cannabis Agency (IMCA), and a full documentation package meeting the country's Procedure 109 import framework. Israel has historically been one of the most accessible international channels for Canadian LPs: with roughly 130,000 active patient licences, a pharmacy-based distribution model, and a regulatory system that recognised Canadian quality standards from its earliest import rules, it absorbs more cannabis imports per capita than any other market in the world. With roughly 130,000 active patient licences, a pharmacy-distribution model that relies on consistent imported supply, and a regulatory framework that has accepted Canadian quality standards from its earliest import rules, it has historically been one of the most accessible international channels for Canadian Licensed Producers.
That picture has become more complicated. A proposed anti-dumping tariff of up to 165% on Canadian imports, still unresolved as of mid-2026, has introduced real uncertainty into supply negotiations. At the same time, the Israeli Ministry of Health has tightened its GMP documentation requirements. The market still wants Canadian flower, but the compliance bar and price scrutiny now favour LPs with a clear quality differentiation story over volume commodity exporters.
This guide covers the full compliance picture for Canadian LPs considering or actively pursuing the Israel channel: the regulatory bodies involved, the documentation requirements under Procedure 109, the quality certifications accepted by IMCA, the Health Canada export permit process, and how to position a Canadian supply offer in a market where the tariff environment has raised the bar for every new agreement.
Understanding the Israel medical cannabis import framework
Israel's medical cannabis import framework is governed by the Israeli Medical Cannabis Agency (IMCA), which sits within the Ministry of Health. IMCA functions as the competent national authority under the international drug control conventions, specifically the Single Convention on Narcotic Drugs, 1961. All imports are classified as dangerous drugs under the Israeli Dangerous Drugs Ordinance (New Version), 1973 and require permits on both the export and import side.
Since January 2020, Israel has allowed imports from countries with comparable regulatory frameworks. Canada qualifies because of its federal licensing regime under the Cannabis Act and Cannabis Regulations. That equivalency is not automatic. IMCA still requires foreign suppliers to demonstrate alignment with Israeli quality standards. Demonstrating that alignment before the application is submitted avoids the most common approval delays.
Israel's quality framework for imported products operates on four tiers:
- IMC-GAP (Good Agricultural and Collection Practice): governs cultivation and post-harvest handling.
- IMC-GMP (Good Manufacturing Practice): covers processing and finished product manufacture, aligned with EU-GMP Annex 7. For more on that standard, see our EU-GMP vs Health Canada GMP comparison for more on that standard.
- IMC-GDP (Good Distribution Practice): covers storage and distribution logistics.
- IMC-GSP (Good Security Practice): applies at multiple points in the supply chain.
Most Canadian flower exporters need to focus on two of these tiers: IMC-GAP and IMC-GMP are the certifications that determine access. Israel accepts recognised equivalent standards from third-party certification bodies. CUMCS-GAP (awarded by Control Union) and ICANN-GAP (awarded by IQC) are both accepted as equivalents to the IMC-GAP standard. This makes Israeli market entry more feasible for Canadian LPs who hold recognised third-party quality certifications without having completed the full EU-GMP process.
Procedure 109 and what Canadian LPs must submit
Procedure 109 is the IMCA's operative framework for approving import applications for medical cannabis. Introduced in the second half of 2022, it replaced earlier ad hoc approval processes with a structured documentation checklist that all foreign suppliers must clear before their products can enter Israel.
The Canada-Israel Procedure 109 Compliance Path: 6 Requirements
- Licence verification: IMCA will verify that the Canadian exporter holds a valid Standard Cultivation or Processing licence issued by Health Canada. Confirmation is typically obtained from Health Canada's public licence database.
- Quality certificate: The supplier must submit a current certificate from a recognised body. Accepted certifications include EU-GMP (most authoritative for IMCA), CUMCS-GAP, or ICANN-GAP. An expired or unrecognised certificate stops the application at this stage.
- Certificate of Analysis (COA): A batch-specific COA from an ISO/IEC 17025-accredited laboratory is required for each shipment. For a full breakdown of what a compliant COA contains, see our guide to reading a cannabis Certificate of Analysis. The COA must cover cannabinoid profile (THC, CBD), microbial limits, heavy metals, pesticide residues, and water activity. IMCA does not accept COAs from non-accredited laboratories, regardless of results.
- Export permit from Health Canada: Canada's obligations under the Single Convention on Narcotic Drugs, 1961 require a per-shipment export permit. Applications must confirm the destination country has issued a corresponding import permit, the export is for medical purposes only, and the LP holds a licence in good standing.
- Israeli importer's import permit: The Israeli distributor must hold a valid import permit from the Israeli Ministry of Health. This is the distributor's responsibility, but Canadian LPs should confirm it is in place before finalising logistics. Missing Israeli-side permits are among the most common causes of shipment delays.
- Packaging and labelling compliance: Products must carry the "IMC-Medical Grade" designation, batch number, cannabinoid profile, and product-specific data in IMCA's required format. Finished, labelled, and packaged flower is the standard for most approved imports.
The 2026 tariff environment and what it means for supply agreements
For any Canadian LP currently evaluating or renegotiating Israeli supply agreements, the tariff situation is the dominant commercial variable right now.
In April 2025, Israel's Ministry of Economy and Industry announced a proposed anti-dumping duty of up to 165% on Canadian cannabis imports, with differentiated rates based on a company-level investigation into pricing. The investigation found that several Canadian exporters were selling into Israel at prices below their domestic cost basis, which Israeli domestic producers argued constituted dumping under WTO definitions.
As of mid-2026, the tariff's status remains contested. The Ministry of Health and the Israeli Competition Authority both publicly opposed the levy, citing reduced product variety, higher patient costs, and potential supply shortages. The Ministry of Finance raised procedural concerns. No final implementation has occurred, but the proposal has not been withdrawn either.
Canadian LPs now face a dual planning requirement:
Scenario A: tariff not enacted
The current compliance and documentation framework applies. Supply agreements can proceed on historical pricing models, though Israeli importers will likely seek pricing contingency clauses to guard against future tariff risk.
Scenario B: tariff enacted (partial or full)
The commercial model changes materially. LPs who command a genuine quality premium, built on indoor cultivation, documented genetics, ISO-tested batch data, and strong COA performance, are better positioned to absorb or justify higher landed costs than volume commodity exporters. Quality differentiation becomes a direct financial argument, not just a procurement preference.
Practically speaking, LPs entering this market should build supply agreements with explicit tariff-contingency clauses, confirm the Israeli importer's legal status and financial standing before committing to volume, and prioritise documentation completeness to remove friction at the IMCA review stage. Our export packaging and labelling guide covers the physical product requirements in detail.
AlphaLeaf as a Canadian export partner for the Israeli pharmaceutical channel
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain the ISO/IEC 17025-certified batch testing, full genetic traceability, and compliance documentation that Israeli pharmaceutical distributors require from a Canadian supply partner. Our quality systems align with the IMC-GMP framework, and our COA data is produced by an ISO 17025-accredited laboratory covering the full panel that IMCA requires for import approval.
Israeli importers and pharmaceutical distributors evaluating Canadian supply in the current tariff environment the combination of premium indoor genetics, batch-consistent hand-trimmed flower, and a complete documentation package is what separates a low-risk, approvable supply agreement from one that creates problems at the IMCA review stage. We supply to partners who require that level of compliance confidence.
If you are evaluating Canadian supply options for the Israeli pharmaceutical channel, contact AlphaLeaf to discuss our documentation package, batch data, and current export authorisation status under the Cannabis Act.
Frequently Asked Questions
What quality certification does a Canadian LP need to export cannabis to Israel?
IMCA accepts several certifications for imported products. EU-GMP is the most recognised and broadly accepted. CUMCS-GAP (awarded by Control Union) and ICANN-GAP (awarded by IQC) are also accepted as equivalents to the IMC-GAP standard. A valid quality certificate from one of these recognised bodies is required before IMCA will review an import application.
Does every shipment to Israel require a new Health Canada export permit?
Yes. Under the Cannabis Regulations, Health Canada issues export permits on a per-shipment basis. Each application must confirm the destination country has issued a corresponding import permit, the export is for medical purposes, and the LP holds a valid licence in good standing with Health Canada.
What is Procedure 109?
Procedure 109 is IMCA's official framework for processing medical cannabis import applications, introduced in the second half of 2022. It sets out the documentation checklist covering licence verification, quality certificates, COA requirements, packaging standards, and permit documentation from both the export and import side.
How has the proposed 165% tariff affected Canadian LP access to the Israeli market?
As of mid-2026, the tariff has not been formally enacted. Announced in April 2025, it remains unresolved due to opposition from the Israeli Ministry of Health, the Competition Authority, and patient advocacy groups. Its effect to date has been to introduce uncertainty into supply negotiations, prompting Israeli importers to seek pricing contingency clauses and prioritise Canadian suppliers who can demonstrate a defensible quality premium at their price point.
Can Canadian LPs ship bulk flower or does Israel require finished packaged product?
Current IMCA requirements generally favour finished, packaged products bearing the IMC-Medical Grade designation. Bulk raw material imports are possible in limited circumstances but require additional approval steps. Most Canadian LP import approvals involve labelled, packaged flower meeting Israeli format and cannabinoid disclosure requirements.
